Pharmacological treatment for Alzheimer's disease: Current approaches and future strategies

Acta Neurologica Taiwanica

Volumn 19, Issue 4, 2010, Pages 228-245

  Fan, Ling Yun ^a   Chiu, Ming Jang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Amyloid hypothesis; Cholinesterase inhibitor; Combination therapy; Disease modifying therapy; Tau protein

Indexed keywords

6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; ATORVASTATIN; BAPINEUZUMAB; CEREBROLYSIN; DIMEBON; DOCOSAHEXAENOIC ACID; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HOMOTAURINE; IMMUNOGLOBULIN; ISOSORBIDE DINITRATE; LETEPRINIM; MEMANTINE; METHYLENE BLUE; OMEGA 3 FATTY ACID; PALIRODEN; PF 04447943; PF 04494700; PLACEBO; RALOXIFENE; RIVASTIGMINE; ROSIGLITAZONE; RRX 03140; SEMAGACESTAT; SEROTONIN 4 AGONIST; SOLANEZUMAB; ST 101; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ALZHEIMER DISEASE; AMNESIA; BEHAVIOR CHANGE; CANCER RISK; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DENTATE GYRUS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; EXCITOTOXICITY; FOOD AND DRUG ADMINISTRATION; HIPPOCAMPUS; HUMAN; INSULIN METABOLISM; NAUSEA; NERVE CELL PLASTICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS;

EID: 79551704780     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Katzman R. Alzheimer's disease is a degenerative disorder. Neurobiol Aging 1989;10:581-582. (Pubitemid 19245478)
2. Bartus R, Dean R, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-414.
3. Struble R, Cork L, Whitehouse P, Price D. Cholinergic innervation in neuritic plaques. Science 1982;216:413-415.
4. Nagai T, McGeer P, Peng J, McGeer E, Dolman C. Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls. Neurosci Lett 1983;36:195-199. (Pubitemid 13080707)
5. Cummings J, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64-S78.
6. Ames D, Bhathal P, Davies B, Fraser J. Hepatotoxicity of tetrahydroaminoacridine. Lancet 1998;1:887.
7. O'Brien J, Eagger S, Levy R. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing 1991;20:129-131.
8. Watkins P, Zimmerman H, Knapp M, Gracon S, Lewis K. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998. (Pubitemid 24099919)
9. Jeffrey LC. Alzheimer's disease: drug therapy. N Engl J Med 2004;351:56-67.
10. Klafki H, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006;129:2840-2855. (Pubitemid 44684507)
11. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2009; 1:CD001190.
12. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-469. (Pubitemid 47450281)
13. Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009;25:2577-2587.
14. Winblad B. Donepezil in severe Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009;24:185-192.
15. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;2: CD001191.
16. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;1:CD00174.
17. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD 005593.
18. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systemic review of the 'real world' evidence. Dement Geriatr Cogn Disord 2009;28: 389-403.
19. Birks J. Chlinesterase inhibitors for Alzheimer's disease. Cochrance Database Syst Rev 2006, 1: CD005593.
20. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of Cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169:557-64. (Pubitemid 37174596)
21. Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69:S14-S22. (Pubitemid 47205655)
22. Blesa R, Ballard C, Orgogozo J, Lane R, Thomas S. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69:S23-S28. (Pubitemid 47205656)
23. Fuschillo C, Ascoli E, Franzese G, Campana F, Cello C, Galdi M, La Pia S, Cetrangolo C. Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. Arch Gerontol Geriatr Suppl 2004; 9:187-194. (Pubitemid 38822866)
24. Johannsen P. Long-term Cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 2004; 18:757-768. (Pubitemid 39410100)
25. Karaman Y, Erdoǧan F, Köseoǧlu E, Turan T, Ersoy A. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19:51-56. (Pubitemid 39664190)
26. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21: 1317-1327. (Pubitemid 41140736)
27. Farlow MR, Lilly ML; ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005;19:5:3.
28. Rountree S, Chan W, Pavlik V, Darby E, Siddiqui S, Doody R. Persistent treatment with Cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;21:1:7.
29. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006, 3: CD006104.
30. Hynd M, Scott H, Dodd P. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583-595. (Pubitemid 38844879)
31. Henry WQ, Frank ML. Alzheimer's disease: the mechanism of disease. N Engl J Med 2010; 362:329-344.
32. Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 2009; 87:1729-1736.
33. Fei Li, Joe ZT. Memory and NMDA receptors. N Engl J Med 2009;361:302-303.
34. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;2:CD 003154.
35. Maidment I, Fox C, Boustani M, Rodriguez J, Brown R, Katona C. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008;42:32-38.
36. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimerdisease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324. (Pubitemid 38101604)
37. Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group. ADL in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006;20:263-268.
38. Schmitt FA, van Dyck CH, Wichems CH, Olin JT, the Memantine MEM-MD-02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 2006;20:255-262.
39. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63.
40. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010;26:263-269.
41. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a Cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83-89.
42. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-212.
43. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489. (Pubitemid 36444329)
44. Resende R, Ferreiro E, Pereira C, Resende de Oliveira C. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008; 155:725-737.
45. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27:796-807. (Pubitemid 46174498)
46. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66:602-604. (Pubitemid 43739900)
47. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009;66:48-54.
48. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 6:1031-1038.
49. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-2070.
50. Medical News Today [homepage on the Internet] [cited 2008 July 31]. Phase II Data On Lilly's Antibody Show It Affects Amyloid Beta, A Protein Believed To Be Associated With Alzheimer's Disease. Available from: http://www. medicalnewstoday.eom/articles/116701.php.
51. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177. (Pubitemid 29327547)
52. Senior K. Dosing in phrase II trial of Alzheimer's vaccine suspened. Lancet Neurol 2002; 1:3.
53. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3: 824-828. (Pubitemid 135706694)
54. Buckwalter MS, Coleman BS, Buttini M, Barbour R, Schenk D, Games D, Seubert P, Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J Neurosci 2006; 26:11437-11441. (Pubitemid 44772174)
55. Kim HD, Kong FK, Cao Y, Lewis TL, Kim H, Tang DC, Fukuchi K. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci Lett 2004; 370:218-223. (Pubitemid 39370882)
56. Zhang S, Wu L, Liu F, Huang B, Huang D, Yang L, Peng Z. Intramembranous fragment of amyloid-beta: A potential immunogen for Alzheimer's disease immunotherapy. Neurochem Res 2009;34:1889-1895.
57. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One 2008;3:e2124.
58. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease i mmunotherapy. CNS Neurol Disord Drug Targets 2009; 8:128-143.
59. Kokjohn T, Roher A. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 2009;8:88-97.
60. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of A beta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299-3310.
61. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64:1563-1572.
62. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223. (Pubitemid 351978111)
63. Aisen PS, Briand R, Saumier D, Laurin J, Duong A, Garceau D. Targeting amyloid with tramiprosate in patients with mild-to-moderate Alzheimer disease. Progress in Neurotherapeutics and Neuropsychopharmacology 2008; 3:111-125. (Pubitemid 351266905)
64. Hampel H, Möller-Spahn F, Berger C, Haberl A, Ackenheil M, Hock C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. Dementia 1995;6:348-354.
65. D'Andrea M. Evidence that immunoglobulin-positive neurons in Alzheimer's disease are dying via the classical antibody-dependent complement pathway. Am J Alzheimers Dis Other Demen 2005;20:144-150. (Pubitemid 40847329)
66. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009;65:24-31.
67. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30: 1728-1736.
68. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005;11:164-169.
69. Giese, K. GSK-3: a key player in neurodegeneration and memory. IUBMB Life 2009;61:516-521.
70. Davenport C, Sevastou I, Hooper C, Pocock, J. Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. J Neurochem 2010;112:552-563.
71. Hampel H, Ewers M, Bürger K, Annas P, Mörtberg A, Bogstedt A, Frölich L, Schröder J, Schönknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Möller HJ, Kurz A, Basun H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70:922-931.
72. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009;16:649-656.
73. Uno Y, Iwashita H, Tsukamoto T, Uchiyama N, Kawamoto T, Kori M, Nakanishi A. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1- methylethoxy) propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice. Brain Res 2009; 1296:148-163.
74. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007;46:8850-8860. (Pubitemid 47208418)
75. Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol 2009;78:927-32.
76. Hattori M, Sugino E, Minoura K, In Y, Sumida M, Taniguchi T, Tomoo K, Ishida T. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem Biophys Res Commun 2008; 374:158-163.
77. Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009; 202:53-65.
78. Claude M, Peter B, Damon j, Kwang M. Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's and Dementia 2008; 4:T167.
79. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, Sultana R. Pin1 in Alzheimer's disease. J Neurochem 2006; 98:1697-1706. (Pubitemid 44298238)
80. Bulbarelli A, Lonati E, Cazzaniga E, Gregori M, Masserini M. Pin1 affects Tau phosphorylation in response to Abeta oligomers. Mol Cell Neurosci 2009; 42:75-80.
81. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, Xia W, Nicholson LK, Lu KP. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006; 440: 528-534.
82. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 2009; 6:446-450.
83. Lermontova N, Lukoyanov N, Serkova T, Lukoyanova E, Bachurin S. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000;129:544-546.
84. Grigor'ev W, Garibova T, Voronina T, Litvinova S, Bachurin S. Effects of chronic administration of dimebon on behavior and memory of SAMP 10 mice. Eksp Klin Farmakol 2009; 72:52-56.
85. Grigorev V, Dranyi O, Bachurin S. Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003; 136:474-477. (Pubitemid 39137308)
86. Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB, Perry G, Smith MA. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010; 1802:212-220.
87. Lermontova N, Redkozubov A, Shevtsova E, Serkova T, Kireeva E, Bachurin S. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca2+ channels. Bull Exp Biol Med 2001; 132:1079-1083. (Pubitemid 34295938)
88. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, Qian J, Marino MJ. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009; 78:1035-1042.
89. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D; dimebon investigators. Effect of dimebon on cognition, ADL, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-215.
90. Recent pfizer press releases [homepage on the Internet]. N.K. & S.F: Pfizer Inc. and Medivation Inc. [Cited: 2010 March 3] Available from: http://www.pfizer.com/news/press-releases/ pfizer-press-releases.jsp
91. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 2009; 451.
92. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, Cattabeni F, Christen Y, Di Luca M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiology of disease 2004; 16:454-460. (Pubitemid 38757325)
93. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer' s disease. FASEB J 2007; 21:2400-2408. (Pubitemid 47230670)
94. Ouyang S, Sun L, Guo S, Liu X, Xu J. Effects of timosaponins on learning and memory abilities of rats with dementia induced by lateral cerebral ventricular injection of amyloid beta- peptide. Di Yi Jun Yi Da Xue Xue Bao 2005; 25:121-126.
95. Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R. Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys 2009; 481:177-182.
96. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Datanase Syst Rev 2009; 1:CD003120.
97. Nishida Y, Yokota T, Takahashi T, Uchihara T, Jishage K., Mizusawa, H. Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. Biochem Biophys Res Commun 2006; 350:530-536. (Pubitemid 44547880)
98. Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, Jishage K, Yamada H, Sasaguri H, Yokota S, Piao W, Tomimitsu H, Saido TC, Yanagisawa K, Terasaki T, Mizusawa H, Yokota T. Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem 2009; 284: 33400-33408.
99. Praticó, D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008:1147:70-78.
100. Isaac MGEKN, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Datanase Syst Rev 2008; 3: CD002854.
101. Lloret A, Badía M, Mora N, Pallardó F, Alonso M, Viña J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 2009; 17:143-149.
102. Li L, Cao D, Kim H, Lester R, Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006; 60:729-739. (Pubitemid 46061359)
103. Höglund K, Blennow K. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 2007; 21:449-462. (Pubitemid 46849181)
104. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 2009; 68:314-325.
105. Sparks D, Kryscio R, Sabbagh M, Connor D, Sparks L, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416-421.
106. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Datanase Syst Rev 2009; 2; CD003160.
107. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74: 956-964.
108. Bazan, N. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 205-211.
109. Calon F, Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 287-293. (Pubitemid 350198857)
110. Pauwels E, Volterrani D, Mariani G, Kairemo K. Fatty acid facts, Part IV: docosahexaenoic acid and Alzheimer's disease. A story of mice, men and fish. Drug News Perspect 2009; 22: 205-213.
111. Kröger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, Ayotte P, Laurin D. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr 2009; 90:184-192.
112. Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 2009; 90:170-176.
113. Lim WS, Gammack JK, Van Niekerk JK, Dangour A. Omega 3 fatty acid for the prevention of dementia. Cochrane Datanase Syst Rev 2006; 1: CD005379.
114. Townsend M, Geary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006; 60:668-676. (Pubitemid 46048484)
115. Fenili D, Brown M, Rappaport R, McLaurin J. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med 2007; 85: 603-611. (Pubitemid 46870891)
116. Kojro E, Postina R. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J Alzheimers Dis 2009; 16: 865-878.
117. Yan S, Bierhaus A, Nawroth P, Stern D. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009; 16: 833-843.
118. Schmidt A, Sahagan B, Nelson R, Selmer J, Rothlein R, Bell J. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 2009; 10: 672-680.
119. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I. RAGE regulates BACEl and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009; 23: 2639-2649.
120. Zhang L, Postina R, Wang Y. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease. Cell Mol Life Sci 2009; 66:3923-3935.
121. Williams B, Granholm A, Sambamurti K. Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neurosci Lett 2007; 413:110-114.
122. Cuello A, Bruno M. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res 2007; 32:1041-1045. (Pubitemid 46726025)
123. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006; 51:29-42. (Pubitemid 43963336)
124. Zhang Q, Liu Y, Yang N, Wan X, Zuo P. Nasal administration of cholera toxin B subunit-nerve growth factor improves the space learning and memory abilities in beta-amyloid protein(25-35)-induced amnesic mice. Neuroscience 2008; 155:234-240.
125. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6: 158-170.
126. Gu H, Long D, Song C, Li X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci Lett 2009; 453:204-209.
127. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11:551-555. (Pubitemid 40691288)
128. Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Experimental Neurology 2008; 211: 574-584.
129. Nagahara AH, Bernot T, Moseanko R, Brignolo L, Blesch A, Conner JM, Ramirez A, Gasmi M, Tuszynski MH. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009; 215:153-159.
130. Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, Chen CP. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 2003; 974:82-87. (Pubitemid 36549222)
131. Lanctôt KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, Houle S, Kozloff N, Verhoeff NP, Kapur S. A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. Am J Geriatr Psychiatry 2007; 15:888-898.
132. Douillet P, Orgogozo JM. What we have learned from the Xaliproden Sanofi-aventis trials. J Nutr Health Aging 2009; 13: 365-366.
133. Geldenhuys W, Van der Schyf C. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease. Curr Top Med Chem 2008; 8:1035-1048.
134. Hirano K, Piers T, Searle K, Miller N, Rutter A, Chapman P. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Life Sci 2009; 84: 558-562.
135. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 2007; 203: 274-278. (Pubitemid 44821167)
136. Maillet M, Robert S, Lezoualc'h F. New insights into serotonin 5-HT4 receptors: a novel therapeutic target for Alzheimer's disease? Curr Alzheimer Res 2004; 1:79-85.
137. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong C. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 2009; 175: 2089-2098.
138. S Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009; 1792:432-443.
139. Kroner, Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 2009;14: 373-379.
140. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009; 29: 9078-9089.
141. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlí T, Spanó A, Gallo D, Mungari P, Consoli D, Bosco D. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010; 288:112-116.
142. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD; Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6:246-254.
143. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005 ;13:950-958.
144. Zhang W, Miao J, Hao J, Li Z, Xu J, Liu R, Cao F, Wang R, Chen J, Li Z. Protective effect of S14G-humanin against beta-amyloid induced LTP inhibition in mouse hippocampal slices. Peptides 2009; 30:1197-1202.
145. Han F, Shioda N, Moriguchi S, Yamamoto Y, Raie AY, Yamaguchi Y, Hino M, Fukunaga K. Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) treatment rescues olfactory bulbectomy-induced memory impairment by activating Ca2+/calmodulin kinase II and protein kinase C in mouse hippocampus. J Pharmacol Exp Ther 2008; 326:127-134.
146. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/ cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 2005; 25: 6887-6897. (Pubitemid 41023156)
147. Timothy N, Rebecca E, Scot S, Ruolun Q, Ellen QW, Frederick N, et al.
148. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154:1166-1181. (Pubitemid 351992052)
149. Medhurst AD, Roberts JC, Lee J, Chen CP, Brown SH, Roman S, Lai MK. Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid overexpressing TASTPM mice. Br J Pharmacol 2009; 157:130-138.
150. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007; 321:1032-1045. (Pubitemid 46762709)
151. Wei ZH, He QB, Wang H, Su BH, Chen HZ. Meta-analysis: the efficacy of nootropic agent cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm 2007; 114:629-634. (Pubitemid 46664058)
152. Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006; 13:43-54.
153. Kazunari H, Hidetoshi Y, Yusaku T, Akiko T, Tetsuo F, Nobor I, et al. A Novel Neurotrophic Agent, T-817MA [1-[3-[2-(1-Benzothiophen-5-yl) Ethoxy] Propyl}-3-azetidinol Maleate], Attenuates Amyloid-β-Induced Neurotoxicity and Promotes Neurite Outgrowth in Rat Cultured Central Nervous System Neurons. J Pharmacol Exp Ther. 2005; 314:252-259.
154. Kimura T, Hong N Phuong T, Ho SA, Tran AH, Ono T, Nishijo H. T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-β peptide. Br J Pharmacol 2009; 157:451-463.
155. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80:600-607.
156. Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T, Wong PC. Modeling of an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med 2010; 2: 13ral. Doi:10.1126/scitranslmed.3000337.
157. Chen TF, Huang RF, Lin SE, Lu JF, Tang MC, Chiu MJ. Folic acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model. J Alzheimers Dis 2010; 20:607-615.